Evogene Ltd. announced a new partnership with Systasy Bioscience GmbH and LMU University Hospital Munich to accelerate the development of therapies for neutrophil‑driven inflammatory diseases, including inflammatory bowel disease.
The collaboration is backed by a pan‑European EUREKA grant and brings together Evogene’s ChemPass AI platform, Systasy’s DNA barcoding technology, and LMU’s clinical expertise. The Weizmann Institute of Science in Rehovot, Israel, also participates in the project, providing additional validation capabilities.
While no specific financial commitment has been disclosed, the structure of the partnership allows for milestone payments and co‑development agreements as the program advances. The alliance positions Evogene to apply its AI‑driven drug design capabilities to a new therapeutic area, potentially opening a new revenue stream and reinforcing the company’s strategy to expand beyond its core AI services.
"We are excited to join forces with Systasy’s and Prof. Klein’s scientific expertise in launching this international effort, bringing therapeutic solutions to inflammatory conditions affecting many patients," said Ofer Haviv, Evogene’s President and CEO. Dr. Sven Wichert, CEO of Systasy, added, "This EUREKA‑funded collaboration marks a pivotal step for Systasy in extending our PathwayProfiler platform to neutrophil biology, and partnering with Evogene’s AI innovation, LMU’s clinical expertise, and Weizmann’s validation strengths positions us to deliver breakthrough therapies addressing unmet needs in hyper‑inflammatory diseases."
The partnership taps into a sizable market of inflammatory and immune‑mediated diseases, where neutrophils play a key role but are currently under‑targeted by existing therapies. By combining Evogene’s AI platform with Systasy’s high‑content multiplexed screening and LMU’s clinical validation, the collaboration aims to identify and validate novel drug candidates within the next few years, potentially accelerating the path to clinical trials.
The collaboration underscores Evogene’s broader strategy to leverage its AI technology across diverse therapeutic indications and to build strategic alliances that can translate computational insights into tangible medical products. The partnership also highlights the growing recognition of neutrophil biology as a therapeutic target and positions the three organizations to address a significant unmet medical need.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.